Trek Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$321K Buy
646
+26
+4% +$11.5K 0.02% 397
2026
Q1
$277K Buy
620
+27
+5% +$12.6K 0.01% 399
2025
Q4
$269K Buy
593
+37
+7% +$15.9K 0.02% 379
2025
Q3
$218K Buy
556
+20
+4% +$8.36K 0.01% 405
2025
Q2
$239K Buy
536
+23
+4% +$10.6K 0.02% 377
2025
Q1
$249K Buy
+513
New +$239K 0.02% 341
2024
Q4
Sell
-439
Closed -$204K 471
2024
Q3
$204K Sell
439
-16
-4% -$7.69K 0.02% 380
2024
Q2
$213K Buy
+455
New +$197K 0.02% 368
2024
Q1
Sell
-12,424
Closed -$5.06M 440
2023
Q4
$5.06M Buy
+12,424
New +$4.59M 0.44% 54

Other funds holding VRTX

Trek Financial's VRTX Position: Q2 2026 in Review

Trek Financial increased its Vertex Pharmaceuticals (VRTX) stake by 4.2% in Q2 2026, buying an estimated $11.5K and bringing the position to 646 shares worth $321K. The position accounts for 0.02% of the portfolio, ranked #397.

Trek Financial first reported a position in VRTX in Q4 2023 and has held it in 9 quarters since. The position peaked at $5.06M in Q4 2023. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Trek Financial held 646 shares of Vertex Pharmaceuticals worth $321K as of Q2 2026.
  • Trek Financial bought 26 Vertex Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Vertex Pharmaceuticals made up 0.02% of Trek Financial's portfolio in Q2 2026, its #397 holding.
  • Trek Financial first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • Trek Financial's Vertex Pharmaceuticals position peaked at $5.06M in Q4 2023.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trek Financial's 13F filing for Q2 2026, filed 13 Aug 2026.